Featured Publications
Antiplatelet regimens following carotid artery revascularization
Lee M, Ahmed ZV, Huang J, Brice A, Arham A, Castro-Dominguez Y, Aboian E, Nagpal S, Smolderen KG, Mena-Hurtado C. Antiplatelet regimens following carotid artery revascularization. American Heart Journal 2022, 253: 48-52. PMID: 35863439, DOI: 10.1016/j.ahj.2022.07.004.Peer-Reviewed Original ResearchConceptsDual antiplatelet therapySingle antiplatelet therapyCarotid artery stentingCarotid endarterectomyAntiplatelet therapyReal-world clinical practiceCarotid artery revascularizationLow adherence ratesArtery revascularizationArtery stentingAdherence ratesClinical practicePatientsTherapyEngland dataHigh percentageRevascularizationAntiplateletEndarterectomyStentingReal‐world VASCADE closure device versus manual compression use and outcomes in patients with severe common femoral artery disease
Nagpal S, Scierka LE, Castro‐Dominguez Y, Kansal D, Kunnirickal S, Hussain Y, Love K, Aboian E, Smolderen KG, Mena‐Hurtado C. Real‐world VASCADE closure device versus manual compression use and outcomes in patients with severe common femoral artery disease. Catheterization And Cardiovascular Interventions 2022, 100: 776-784. PMID: 36129818, DOI: 10.1002/ccd.30405.Peer-Reviewed Original ResearchConceptsPeripheral vascular interventionsManual compressionClosure deviceCommon femoral artery diseaseVascular Quality Initiative databaseFemoral artery diseasePropensity-matched cohortPseudoaneurysm rateRetroperitoneal bleedingArtery diseaseRetrospective reviewMean ageBaseline variablesInstitutional databaseNonsignificant reductionNonsignificant decreaseVascular interventionsMortality ratePatientsCompression useCollagen plugDiseaseInitiative databaseProcedural metricsDevice usePeripheral Artery Disease Screening in the Community and 1-Year Mortality, Cardiovascular Events, and Adverse Limb Events
Smolderen K, Ameli O, Chaisson C, Heath K, Mena-Hurtado C. Peripheral Artery Disease Screening in the Community and 1-Year Mortality, Cardiovascular Events, and Adverse Limb Events. AJPM Focus 2022, 1: 100016. PMID: 37791014, PMCID: PMC10546509, DOI: 10.1016/j.focus.2022.100016.Peer-Reviewed Original ResearchMajor adverse limb eventsPeripheral artery diseaseAdverse limb eventsMajor cardiovascular eventsPeripheral artery disease (PAD) screeningArtery diseaseCardiovascular eventsLimb eventsCause mortalityOne-yearDisease screeningPeripheral vascular interventionsCardiovascular risk managementCause mortality ratesHome health visitsMedicare Advantage beneficiariesCardiovascular medicationsHealth visitsRevascularization proceduresHealthcare utilizationLandmark analysisSimilar riskVascular interventionsClaims dataMortality rateRisk profiles, access to care, and outcomes in Hispanics hospitalized for lower extremity peripheral artery disease
Luna P, Harris K, Castro-Dominguez Y, Algara M, Severiche-Mena C, Smolderen KG, Mena-Hurtado C. Risk profiles, access to care, and outcomes in Hispanics hospitalized for lower extremity peripheral artery disease. Journal Of Vascular Surgery 2022, 77: 216-224.e15. PMID: 36037965, DOI: 10.1016/j.jvs.2022.08.021.Peer-Reviewed Original ResearchConceptsPeripheral artery diseaseLower extremity peripheral artery diseaseNon-Hispanic whitesEmergency departmentPAD careArtery diseaseRisk factorsSevere peripheral artery diseaseChronic limb-threatening ischemiaRisk profileNational Inpatient Sample dataCardiovascular risk factorsLimb-threatening ischemiaPatients' sociodemographic characteristicsWorse clinical outcomesMultivariable logistic regressionAssociation of ethnicityLength of stayHealth care consumptionHealth care coveragePAD hospitalizationsPrior amputationEndovascular revascularizationED admissionRenal failurePatient-level and external factors in the use of drug-coated balloons and drug-eluting stents in femoropopliteal endovascular interventions
Castro-Dominguez Y, Smolderen KG, Pichert M, Alabi O, Romain G, Huang J, Lee M, Ahmed Z, Peri-Okonny PA, Arham A, Brice A, Chaar CO, Stacy MR, Mena-Hurtado C. Patient-level and external factors in the use of drug-coated balloons and drug-eluting stents in femoropopliteal endovascular interventions. Journal Of Vascular Surgery 2022, 76: 1675-1680. PMID: 35868423, DOI: 10.1016/j.jvs.2022.06.093.Peer-Reviewed Original ResearchConceptsDrug-coated balloonsDrug-eluting stentsBare metal stentsDES useFemoropopliteal endovascular interventionEndovascular interventionMedian odds ratioFemoropopliteal diseaseLesion characteristicsPrimary treatmentChronic kidney disease stage 4Adjusted median odds ratioVascular Quality Initiative registryAppropriate use guidelinesPrior anticoagulant usePatient-level factorsPoor functional statusTrans-Atlantic InterPlain balloon angioplastyPatient-level characteristicsFavorable patency ratesHierarchical logistic regression modelsLogistic regression modelsMeta-analysis publicationsRutherford classificationPROGNOSTIC VALIDITY OF FRAILTY ASSESSMENT TOOLS IN PREDICTION OF MORTALITY AND MAJOR AMPUTATION IN PATIENTS UNDERGOING REVASCULARIZATION FOR LOWER EXTREMITY ARTERIAL DISEASE
Nikooie R, Smolderen K, Al-Damluji M, Meng C, Dai F, Nanna M, Sumpio B, Henke P, Mena-Hurtado C. PROGNOSTIC VALIDITY OF FRAILTY ASSESSMENT TOOLS IN PREDICTION OF MORTALITY AND MAJOR AMPUTATION IN PATIENTS UNDERGOING REVASCULARIZATION FOR LOWER EXTREMITY ARTERIAL DISEASE. Journal Of The American College Of Cardiology 2022, 79: 1779. DOI: 10.1016/s0735-1097(22)02770-x.Peer-Reviewed Original ResearchCAROTID ARTERY STENTING AND ANGIOPLASTY WITH PROTECTION IN PATIENTS AT HIGH-RISK FOR ENDARTERECTOMY: SAPPHIRE WORLDWIDE REGISTRY OUTCOMES
Harris K, Smolderen K, Mena-Hurtado C. CAROTID ARTERY STENTING AND ANGIOPLASTY WITH PROTECTION IN PATIENTS AT HIGH-RISK FOR ENDARTERECTOMY: SAPPHIRE WORLDWIDE REGISTRY OUTCOMES. Journal Of The American College Of Cardiology 2022, 79: 640. DOI: 10.1016/s0735-1097(22)01631-x.Peer-Reviewed Original ResearchFrailty and outcomes following revascularization of lower-extremity peripheral artery disease: Insights from the Vascular Quality Initiative (VQI)
Al-Damluji MS, Smolderen KG, Meng C, Dai F, Nanna MG, Sumpio B, Henke P, Mena-Hurtado C. Frailty and outcomes following revascularization of lower-extremity peripheral artery disease: Insights from the Vascular Quality Initiative (VQI). Vascular Medicine 2022, 27: 251-257. PMID: 35485400, DOI: 10.1177/1358863x221083701.Peer-Reviewed Original ResearchConceptsRisk Analysis IndexVascular Quality InitiativeLower extremity revascularizationFrailty screening toolsMFI-5Lower extremity peripheral artery diseaseScreening toolFrailty detectionAddition of frailtyPAD risk factorsPeripheral artery diseasePAD populationRevascularization typeVascular cohortMajor amputationPerioperative outcomesArtery diseaseFrailty indexFrailty toolsAdjusted analysisUnplanned amputationRisk factorsHigher oddsPredictive valuePatientsThe Nevada peripheral artery disease screening effort in a Medicare Advantage population and subsequent mortality and major adverse cardiovascular event risk
Smolderen K, Heath K, Scherr T, Bauzon S, Howell A, Mena-Hurtado C. The Nevada peripheral artery disease screening effort in a Medicare Advantage population and subsequent mortality and major adverse cardiovascular event risk. European Journal Of Vascular And Endovascular Surgery 2022, 63: e98. DOI: 10.1016/j.ejvs.2022.06.013.Peer-Reviewed Original ResearchGuideline-Directed Medical Therapy and Long-Term Mortality and Amputation Outcomes in Patients Undergoing Peripheral Vascular Interventions
Smolderen K, Romain G, Provance J, Scierka L, Mao J, Goodney P, Henke P, Sedrakyan A, Mena-Hurtado C. Guideline-Directed Medical Therapy and Long-Term Mortality and Amputation Outcomes in Patients Undergoing Peripheral Vascular Interventions. JACC Cardiovascular Interventions 2023, 16: 332-343. PMID: 36792257, PMCID: PMC10359106, DOI: 10.1016/j.jcin.2022.09.022.Peer-Reviewed Original ResearchConceptsGuideline-directed medical therapyPeripheral vascular interventionsMedical therapyVascular interventionsEnzyme inhibitors/angiotensin receptor blockersVascular Quality Initiative registryAngiotensin receptor blockersLong-term mortalityRisk of amputationRisk of mortalityNational quality registryQuality improvement effortsAmputation outcomesAmputation riskMajor amputationAntiplatelet therapyCause mortalityReceptor blockersMean ageVascular careQuality registryObservational studyMortality riskHigh riskAmputation dataUse of drug-coated balloons and stents in patients with femoropopliteal artery disease and severe chronic kidney disease
Castro-Dominguez Y, Smolderen K, Romain G, Turner J, Mena-Hurtado C. Use of drug-coated balloons and stents in patients with femoropopliteal artery disease and severe chronic kidney disease. Vascular Medicine 2023, 28: 150-152. PMID: 36710497, DOI: 10.1177/1358863x221148521.Peer-Reviewed Original ResearchHealth status and cognitive function for risk stratification in chronic coronary and peripheral artery disease.
Smolderen K, Mena-Hurtado C, Eikelboom J, Bosch J, Xie F, Ramasundarahettige C, Bhatt D, Anand S. Health status and cognitive function for risk stratification in chronic coronary and peripheral artery disease. European Journal Of Preventive Cardiology 2022, 30: 535-545. PMID: 36444513, DOI: 10.1093/eurjpc/zwac282.Peer-Reviewed Original ResearchConceptsCoronary artery diseaseDigit Symbol Substitution TestVisual analog scaleEQ visual analogue scaleHealth statusLimb eventsCAD cohortCognitive functionArtery diseaseEQ-5DHierarchical Cox regression modelsMajor adverse cardiovascular eventsStable coronary artery diseaseAdverse cardiovascular eventsPeripheral artery diseasePopulation attributable riskCox regression modelOverall health statusCognitive function assessmentCOMPASS trialPAD cohortCardiovascular eventsPAD patientsRisk stratificationAnalog scaleArtificial Intelligence, Computational Simulations, and Extended Reality in Cardiovascular Interventions
Samant S, Bakhos J, Wu W, Zhao S, Kassab G, Khan B, Panagopoulos A, Makadia J, Oguz U, Banga A, Fayaz M, Glass W, Chiastra C, Burzotta F, LaDisa J, Iaizzo P, Murasato Y, Dubini G, Migliavacca F, Mickley T, Bicek A, Fontana J, West N, Mortier P, Boyers P, Gold J, Anderson D, Tcheng J, Windle J, Samady H, Jaffer F, Desai N, Lansky A, Mena-Hurtado C, Abbott D, Brilakis E, Lassen J, Louvard Y, Stankovic G, Serruys P, Velazquez E, Elias P, Bhatt D, Dangas G, Chatzizisis Y. Artificial Intelligence, Computational Simulations, and Extended Reality in Cardiovascular Interventions. JACC Cardiovascular Interventions 2023, 16: 2479-2497. PMID: 37879802, DOI: 10.1016/j.jcin.2023.07.022.Peer-Reviewed Original ResearchConceptsArtificial intelligenceExtended realityVirtual clinical trialsComputer scientistsComputational technologiesIntelligenceMedical technology innovatorsTechnology innovatorsComputational simulationsTechnologyRealityApplicationsBiomedical engineersBioinformaticsSimulationsDevice industryVisualizationConstraintsEngineersExpertsRecent advancesPlanningObstaclesLongitudinal Pathways Between Physical Activity, Depression, and Perceived Stress in Peripheral Artery Disease.
Yazgan I, Bartlett V, Romain G, Cleman J, Petersen-Crair P, Spertus J, Hardt M, Mena-Hurtado C, Smolderen K. Longitudinal Pathways Between Physical Activity, Depression, and Perceived Stress in Peripheral Artery Disease. Circulation Cardiovascular Quality And Outcomes 2023, 16: 544-553. PMID: 37470195, PMCID: PMC10561081, DOI: 10.1161/circoutcomes.122.009840.Peer-Reviewed Original ResearchConceptsPhysical activityPAD diagnosisDepressive symptomsLower physical activity scoresPerceived stressVascular specialty clinicsPeripheral artery diseasePhysical activity scoreSignificant depressive symptomsPatient Health QuestionnaireBehavioral health approachesSubsequent depressive symptomsINTERHEART studySymptomatic PADCardiovascular eventsPAD symptomsArtery diseaseInitial presentationActivity scoreSpecialty clinicHealth QuestionnairePatient's abilityTreatment goalsPAD managementPerceived Stress ScaleInter-Rater Reliability for the Amputation Endpoint in the National Vascular Quality Initiative
Smolderen K, Romain G, Scierka L, Cleman J, Rahman M, Siddiqui W, Lau F, Mao J, Akhlaghi N, Higaki A, Fowler X, Carroll M, Telma K, Alvermann T, Baribeau V, Goodney P, Mena-Hurtado C. Inter-Rater Reliability for the Amputation Endpoint in the National Vascular Quality Initiative. JACC Cardiovascular Interventions 2024, 17: 622-631. PMID: 38479964, DOI: 10.1016/j.jcin.2024.01.003.Peer-Reviewed Original ResearchConceptsElectronic health recordsElectronic health record reviewAmputation dataPeripheral arterial diseaseInterrater reliabilityVQI registryAcademic health systemTrained data collectorsNational quality registryInter-rater reliabilityEvaluate interrater reliabilityNational reporting systemHealth recordsQuality registryHealth systemCurrent Procedural Terminology codesInter-raterVascular Quality Initiative registryVascular Quality InitiativeProcedural Terminology codesNational Vascular Quality InitiativeRegistryQuality InitiativeAmputationSpearman's rSecondary interventions following open vs endovascular revascularization for chronic limb threatening ischemia in the BEST-CLI trial
Conte M, Azene E, Doros G, Gasper W, Hamza T, Kashyap V, Guzman R, Mena-Hurtado C, Menard M, Rosenfield K, Rowe V, Strong M, Farber A. Secondary interventions following open vs endovascular revascularization for chronic limb threatening ischemia in the BEST-CLI trial. Journal Of Vascular Surgery 2024, 79: 1428-1437.e4. PMID: 38368997, DOI: 10.1016/j.jvs.2024.02.005.Peer-Reviewed Original ResearchIntention-to-treatBEST-CLIChronic limb-threatening ischemiaOpen bypassRe-interventionBEST-CLI trialCohort 1Limb-threatening ischemiaSecondary analysisCox regression modelsOpen armMultivariate Cox regression modelRegression modelsDuration of follow-upTrial cohortCohortAnalyzed dataRandomized trialsFollow-upReduced hazardEndovascular revascularizationCLTIInitial treatmentTrialsStudy endpointExamining Outcomes in Patients Admitted With Comorbid Peripheral Artery Disease and Microvascular Disease
Grubman S, Algara M, Smolderen K, Luna P, Walenczyk K, Scierka L, Cleman J, Siddiqui W, Romain G, Mena‐Hurtado C. Examining Outcomes in Patients Admitted With Comorbid Peripheral Artery Disease and Microvascular Disease. Journal Of The American Heart Association 2024, 13: e030710. PMID: 38166496, PMCID: PMC10863818, DOI: 10.1161/jaha.123.030710.Peer-Reviewed Original ResearchConceptsPeripheral artery diseaseMajor adverse cardiac eventsAdverse cardiac eventsMicrovascular diseaseMinor amputationHospital mortalityCardiac eventsArtery diseaseNational Readmission DatabaseFurther prospective researchNumber of patientsCommon risk factorsMultiple logistic regressionMajor amputationBaseline factorsFinal cohortCox regressionAdverse outcomesPAD groupSecondary diagnosisRisk factorsAnnual admissionsObservational studyPrevalent conditionHigh riskThe Vascular Quality Initiative assessment of the Bard Lifestent for the treatment of popliteal artery occlusive disease
Bertges D, Eldrup-Jorgensen J, Eskandari M, Hamdan A, Mena-Hurtado C, Mewissen M, Smith T, Woo E, Cronenwett J, Initiative S. The Vascular Quality Initiative assessment of the Bard Lifestent for the treatment of popliteal artery occlusive disease. Journal Of Vascular Surgery 2023, 78: 1489-1496.e1. PMID: 37648091, DOI: 10.1016/j.jvs.2023.08.122.Peer-Reviewed Original ResearchConceptsTarget lesion revascularizationChronic limb-threatening ischemiaTarget vessel revascularizationMajor adverse eventsLimb-threatening ischemiaPopliteal arteryLesion revascularizationMajor amputationVessel revascularizationHemodynamic successSecondary patencyAdverse eventsOcclusive diseaseProcedural successSingle-arm prospective studyProximal popliteal arterySustained clinical successPrimary efficacy outcomePrimary safety outcomeArtery occlusive diseaseComposite primary endpointPrimary-assisted patencyKaplan-Meier analysisSuperficial femoral arteryMajority of stentsRenal Denervation for the Treatment of Hypertension: A Scientific Statement From the American Heart Association
Cluett J, Blazek O, Brown A, East C, Ferdinand K, Fisher N, Ford C, Griffin K, Mena-Hurtado C, Sarathy H, Vongpatanasin W, Townsend R, Disease O. Renal Denervation for the Treatment of Hypertension: A Scientific Statement From the American Heart Association. Hypertension 2024, 81: e135-e148. PMID: 39101202, DOI: 10.1161/hyp.0000000000000240.Peer-Reviewed Original ResearchRenal denervationBlood pressureEfficacy of renal denervationUS Food and Drug AdministrationRandomized clinical studyRenal sympathetic nervesNovel treatment strategiesBlood pressure control ratesLonger-term efficacyIndividual patient responseLowering blood pressureFood and Drug AdministrationSpectrum of hypertensionTreatment of hypertensionControl blood pressureUncontrolled blood pressureMultiple ongoing studiesCatheter-based proceduresAmerican Heart AssociationHigh blood pressureTherapeutic optionsSafety profileCardiovascular morbidityControl rateHypertension specialistsTwelve-Month Health Status Response Following Peripheral Vascular Intervention for Femoropopliteal Lesions Using Zilver PTX Databases Focusing on the Role of Preprocedural Health Status, Comorbid Risks, and Global Setting
Smolderen K, Romain G, Cleman J, Callegari S, Peri-Okonny P, Mena-Hurtado C. Twelve-Month Health Status Response Following Peripheral Vascular Intervention for Femoropopliteal Lesions Using Zilver PTX Databases Focusing on the Role of Preprocedural Health Status, Comorbid Risks, and Global Setting. Journal Of Vascular Surgery 2024 PMID: 39214426, DOI: 10.1016/j.jvs.2024.08.035.Peer-Reviewed Original ResearchMinimal clinically important differenceEQ-5D indexHealth statusPeripheral vascular interventionsPeripheral arterial diseaseEQ-5DNon-respondersValue-based careEuroQol-5D-3LClinically important differenceSecondary data analysisFemoropopliteal peripheral vascular interventionsStable health statusLogistic regression modelsArtery diseaseSymptomatic peripheral arterial diseaseStatus responseTailored resourcesVascular interventionsSingle-arm studyImportant differenceCarotid artery diseaseComorbidity riskEnrolling centersPatient characteristics